Short-term efficacy and safety of lasmiditan, a novel 5-HT1F receptor agonist, for the acute treatment of migraine: a systematic review and meta-analysis

Short-term efficacy and safety of lasmiditan, a novel 5-HT1F receptor agonist, for the acute treatment of migraine: a systematic review and meta-analysis

Abstract Background Migraine has been recognized as one of common diseases in the world whose current treatment options are not ideal. Lasmiditan, an oral 5-hydroxytryptamine (HT)1F receptor agonist, appears more promising for the acute treatment of migraine because of considerably better effect pro...

Full description

Bibliographic Details
Main Authors: Min Hou, Haiyan Xing, Chen Li, Xianfeng Wang, Dongmei Deng, Juan Li, Pan Zhang, Jianhong Chen
Format: Article
Language:English
Published: BMC 2020-06-01
Series:The Journal of Headache and Pain
Subjects:
Migraine
Lasmiditan
5-HT1F receptor agonist
Meta-analysis
Online Access:http://link.springer.com/article/10.1186/s10194-020-01138-x

Internet

http://link.springer.com/article/10.1186/s10194-020-01138-x

Similar Items